Filarial DiseasesTranslation

 

  • Target disease: Filarial diseases
  • Main partners (since project start): National Museum of Natural History Paris (MNHN), France; Northwick Park Institute for Medical Research, UK; University Hospital of Bonn, Institute of Medical Microbiology, Immunology and Parasitology, Germany.
  • Start date: 
  • Funding (since project start): Department for International Development (DFID), UK; Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders; United States Agency for International Development (USAID), USA.

 

Overall Objective:

  • Develop a macrofilaricide for filarial disease

 

Oxfendazole is currently under development for the treatment of neurocysticercosis and trichuriasis. Based on highly encouraging pre-clinical efficacy data, DNDi is exploring the possibility of repurposing oxfendazole as a macrofilaricidal treatment for filarial indications.

 

DNDi intends to initiate a first-in-human trial and complete formulation development.

 

Last update: February 2019